Hansoh Pharmaceutical Group Company Limited (stock code: 3692) has announced the completion of its issuance of HK$4,680 million zero coupon convertible bonds due 2033, finalized on February 3, 2026. According to the announcement, the bonds are expected to be admitted to trading and listing on the Vienna MTF operated by the Vienna Stock Exchange on or around February 4, 2026.

The net proceeds from this issuance amount to approximately HK$4,640 million, translating to a net issue price of about HK$56.90 per Conversion Share based on the initial conversion price. Approximately 65% of these funds are earmarked for drug research and development, as well as in-licensing projects, focusing on the progression of an innovative pipeline that has already advanced more than 70 clinical trials covering over 40 unique drug candidates. Around 25% of the proceeds will go toward constructing and upgrading R&D centers and production lines, while the remaining 10% is allocated to working capital and other general corporate purposes.

Hansoh Pharmaceutical intends to fully utilize these net proceeds by 2031, enabling further investment in mid-to-late stage clinical development, the expansion of its manufacturing facilities, and additional R&D projects. The company’s plans include building new production lines for anticipated products in areas such as oncology, metabolic diseases, and immunology, while continuing to refine its global R&D capabilities and industrial base.